Ovarian cancer. an institutional review of patterns of care, health insurance and prognosis.
The purpose of this study was to investigate the prognostic importance of the health insurance status in 145 consecutive patients with ovarian cancer diagnosed between 1984 and 1996. All patients had basic (Type III) insurance to cover outpatient treatment and hospital expenses for a per diem flat fee; some patients had one of two types of supplemental private insurance (Type I and Type II) to cover the treatment by physicians of their choice and fee-for-service hospital treatment. The prognostic impact of health insurance was evaluated by multivariate statistical methods. The median follow-up was 81.9 months (range: 21-181); the 5-year probability of survival was 72% (standard error of the mean (SEM) 9.8%) for stage I, 53% (SEM 16.2%) for stage II, 17% (SEM 5. 9%) for stage III and 11% (SEM 5.5%) for stage IV cancer. Age, stage, histological grade and debulking surgery were independent predictors of survival in multivariate proportional hazards regression analysis. Patients with private insurance were younger and received more chemotherapy than patients with basic insurance. In multivariate analysis, insurance was an independent predictor of survival: patients with Type II insurance had a hazard ratio of 2.31 (95% confidence interval (CI): 1.05-5.04), and patients with Type III insurance had a hazard ratio of 3.30 (95% CI 1.52-7.17) compared with the reference group of Type I insured patients. Health insurance status was an independent predictor of survival in ovarian cancer. Research is needed to devise strategies to improve the medical care of patients with basic insurance.
Balli
S
S
Institute of Medical Oncology, University of Bern, Inselspital, CH-3010, Bern, Switzerland.
Fey
M F
MF
Hänggi
W
W
Zwahlen
D
D
Berclaz
G
G
Dreher
E
E
Aebi
S
S
D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000191:economics*; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D007348:Insurance, Health; D007350:Insurance, Hospitalization / Q000191:economics; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000191:economics / Q000628:therapy*; D017149:Private Sector; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D016019:Survival Analysis
D000970:Antineoplastic Agents